ImmunoGen, Inc.

Good morning and welcome to Immunogen's first quarter 2023 financial and operating results conference call. Today's conference is being recorded. At this time, I'd like to turn the call over to Annabelle Chan, head of investor relations. Please go ahead.

Good morning and thank you for joining today's call. Earlier today, we issued a press release that includes a summary of our recent operating progress and first quarter financial results. This press release, the recording of this call, and an updated corporate deck can be found under the Investors and Media section of our website at immunogen.com. With me today are Mark Ennedy, our President and CEO, Anna Birkenblit, our Chief Medical Officer, and Rene Lentini, our Interim CFO. Michael Vasconcellos, our EVP of Research, Development, and Medical Affairs, Isabella Calafonos, our Chief Commercial Officer, and Todd Tallarico, our VP of Market Access. will also join us for Q&A. During today's call, we will review recent accomplishments for the business, our financial results, and highlight upcoming anticipated events. We will be making forward-looking statements based on our current expectations and beliefs. These statements are subject to risks and uncertainties, and our actual results may differ materially. Please consult the risks outlined in our press release issued this morning, in the risk factor section of our most recent annual report on Form 10-K, and on our other FCC filings, which are available at scc.gov and immunogen.com. And with that, I'll turn the call over to Mark.

Thanks, Annabelle. Good morning, everyone, and thank you for joining us today. I'd like to preface this call by saying that the focus of today's discussion will be on Elihir's commercial performance and on our ongoing development programs beyond Mirasol.